Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) Shares Outstanding (Diluted Average) (2021 - 2025)

Arcadia Biosciences' Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) changed 0.35% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, changed 0.35%, while the annual FY2025 figure was $1.4 million, 0.35% changed from the prior year.
  • Shares Outstanding (Diluted Average) reached $1.4 million in Q4 2025 per RKDA's latest filing, roughly flat from $1.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $22.2 million in Q3 2021 to a low of $532016.0 in Q4 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $3.3 million, with a median of $1.4 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Diluted Average): plummeted 97.45% in 2022, then skyrocketed 106.37% in 2023.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $532016.0 in 2021, then rose by 12.66% to $599389.0 in 2022, then surged by 106.37% to $1.2 million in 2023, then grew by 10.22% to $1.4 million in 2024, then rose by 0.35% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Shares Outstanding (Diluted Average) are $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $1.4 million (Q2 2025).